Ancillare Appoints Vice President of Supply Chain

Christopher Calabretta, an accomplished procurement and operations executive, brings three decades of supply chain expertise to Ancillare’s leadership team.

Horsham, Pa. — September 29, 2021. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it has appointed Christopher Calabretta as Vice President of Supply Chain.

Calabretta brings three decades of experience in supply chain for global healthcare and consumer products companies, including Johnson & Johnson, McNeil Consumer Products, Campbell Soup Company, and FritoLay®. His career is marked by several successful enterprise-wide initiatives carried out on a global scale, driven by a passion for delivering value to patients and consumers worldwide.

In his new role, Calabretta will lead Ancillare’s Procurement, Logistics, and U.S. Distributions teams, and will help advance the organization’s strategic growth initiatives.

“We are proud to welcome Christopher to our organization,” said Dr. Joanne Santomauro, Chief Executive Officer. “His depth of expertise in global supply chains will be a tremendous asset in Ancillare’s mission to innovate the global CTASC.”

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC TM) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare Expands Sourcing and Export Capabilities to Include Medicinal Products

Leading life sciences supply chain organization acquires NG BV, a Netherlands-based company authorized to procure, supply, and export medicinal products.

Horsham, Pa. — September 23, 2021. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced its acquisition of NG BV in the Netherlands.

As a company with a Wholesale Distribution Authorization (WDA), NG BV will market, procure, supply, and export medicinal products. The acquisition deepens Ancillare’s supply chain capabilities in the medicinal products space, allowing even greater control and supply chain transparency for Sponsors globally.

“The purchase of NG BV is a significant milestone for our organization,” said Dr. Joanne Santomauro, Chief Executive Officer. “The ability to manage medicinal products that facilitate clinical trials reinforces our position as a single-source partner for CTASC management and significantly supports the industry-unique Ancillare Turn-Key Operation (A-TKO™).”

Cathy Porretti, Chief Global Operation Officer, added: “We know many Sponsors value single vendor relationships to ensure smooth, timely trials. And through this acquisition and expansion, we are able to bring our proven methodology to another key part of the trial’s lifecycle.”

In the coming months, more expansion efforts will take place to strengthen Ancillare’s global supply chain infrastructure and service offering. For the most up-to-date information on Ancillare’s CTASC capabilities, visit Ancillare.com.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare, a Tier 1 Diversity Supplier, Sponsors DCAT 2021 Women’s Virtual Networking Breakfast

Ancillare, a Tier 1 Diversity Supplier, Sponsors DCAT 2021 Women’s Virtual Networking Breakfast

Ancillare, a woman-owned business serving top global biopharmaceutical companies, will sponsor the annual women’s networking event on March 24.

Horsham, Pa. — March 24th, 2021. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, is proud to sponsor the DCAT Women’s Networking Breakfast on Wednesday, March 24.

Ancillare, a woman-owned business by the Women’s Business Enterprise National Council (WBENC), is proud to sponsor the event, which is presented annually by DCAT’s Alliance for Industry Women Committee. This year, the event features keynote speaker Erica Dhawan, CEO and Co-Founder of strategy consulting company Cotential. During the live presentation, Dhawan will speak about effective collaboration as discussed in her book “Get Big Things Done: The Power of Connectional Intelligence,” highlighting the skills needed to build stronger organizational cultures. Participants will learn how to solve problems and drive innovation by applying Connectional Intelligence (CxQ) to communication in the digital age.

“As a woman-owned business, Ancillare has a unique opportunity — and responsibility — to support women’s advancement in healthcare and pharmaceuticals,” said Dr. Joanne Santomauro, Chief Executive Officer. “We are proud to sponsor an event that promotes the power of engaged teams and innovative mindsets, which have been foundational to Ancillare’s growth.”

The Women’s Networking Breakfast, typically held during DCAT Week in New York City, is a members-only event for women in the pharmaceutical industry. This year, the virtual session will feature digital networking opportunities and a live Q&A with Dhawan.

Further details about the DCAT Women’s Networking Breakfast are available at https://dcat.org/wnb.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare Receives Medical Device Establishment License in Canada

Ancillare, the industry leader in Clinical Trial Ancillary Supply Chain (CTASC™), obtains authorization to distribute medical devices in Canada.

Horsham, Pa. — January 14th, 2021. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, announced it obtained its Medical Device Establishment License (MDEL) in August of 2020 and is now actively importing medical devices in support of Phase I-IV clinical trials.

The MDEL, which allows for the import and sale of medical devices, will serve to strengthen Ancillare’s global distribution network.

Ancillare applied for the MDEL in response to the Canada Border Services Agency’s (CBSA) Single Window Initiative, which enacted new licensing requirements for importers of medical devices and other goods under Health Canada jurisdiction. The license demonstrates compliance to Health Canada’s Medical Device Regulation (MDR), and gives Ancillare the ability to import registered medical devices for clinical use in Canada.

“With an MDEL, Ancillare can better support our Sponsors by facilitating medical device imports,” said Dr. Joanne Santomauro, Chief Executive Officer. “Maintaining regulatory knowledge and compliance is among our key value offerings, and represents just one example of our ongoing efforts to strengthen Ancillare’s global distribution capabilities.”

To learn more about Ancillare’s service offering, including global distribution and regulatory support, visit Ancillare.com/Services.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare Appoints Dr. Georgia Crozier to Medical Director

Philadelphia-based optometrist Dr. Georgia Crozier joins Ancillare, leader in Clinical Trial Ancillary Supply Chain™, to consult on clinical trial planning.

Horsham, Pa. — November 12th, 2020. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it has appointed Georgia Crozier, OD, MS as a Medical Director to serve on its growing Clinical Development Team.

Dr. Crozier will leverage years of experience at multiple clinical sites to serve as a Subject Matter Expert for clinical trial planning and execution. Working directly with Ancillare’s internal teams and with Sponsors, Dr. Crozier will consult on matters of compliance for robust CTASC design.

An optometrist who has worked at a number of clinical sites, Dr. Crozier brings over 35 years of experience in her field —as a clinical investigator, medical consultant, and lecturer. She is a graduate of Pennsylvania College of Optometry at Salus University, and currently serves as the Director of the Moore Eye Institute Vision Rehabilitation Center.

“We are thrilled to bring on Dr. Crozier as a Medical Director,” said Dr. Joanne Santomauro, Chief Executive Officer. “Expanding our Clinical Development Team will further streamline the selection of ancillary supplies that meet increasingly demanding protocols and ever-changing global regulations. Ophthalmologic studies tend to be highly specialized with a broad range of supply and equipment needs, and we are excited to have Dr. Crozier’s expertise in-house for our Sponsors and clients.”

Dr. Crozier will serve as Medical Director alongside Dr. John Fitzgerald, who was recently appointed to the same role. The two physicians will work as a team and leverage their individual areas of expertise to better serve Ancillare’s Sponsors.

To read full biographies of Ancillare’s Medical Directors and learn more about the company’s Subject Matter Experts, visit https://www.ancillare.com/about/#leadership.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare Opens New Distribution Facility in the Netherlands for the EU Clinical Trial Ancillary Supply Chain

Ancillare, the world leader in Clinical Trial Ancillary Supply Chain (CTASC™), announced that its new Distribution Facility will open December 1.

Horsham, Pa. — November 9th, 2020. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it will open a new Distribution Facility in the Netherlands on December 1, 2020.

Ancillare currently holds over a dozen strategic depots to manage the flow of supplies to clinical trial sites around the globe. In addition to Ancillary Supply Chain storage and distribution, the new facility will be home to Ancillare’s European headquarters.

“We are proud to expand our global footprint through our new Netherlands facility,” said Dr. Joanne Santomauro, Chief Executive Officer. “This strategic distribution hub will allow for more streamlined Clinical Trial Ancillary Supply Chains across Europe, and will help us continue reaching more trial sites, and patients, around the world.”

Over the past several months, Ancillare’s global operations teams have worked diligently to ensure that the new facility opens successfully on December 1. The company has obtained all necessary licenses and approvals for business operations in the EU, and is working to ensure a seamless transition for Sponsors.

To learn more about Ancillare’s Global Distribution Network, visit Ancillare.com/About.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.